Alps Advisors Inc X Biotech Inc. Transaction History

Alps Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$8.64 - $11.71 $303,920 - $411,910	-35,176 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$10.95 - $16.07 $22,491 - $33,007	-2,054 Reduced 5.52%	35,176 $392,000
Q3 2021 Nov 15, 2021	SELL	$12.95 - $18.24 $29,215 - $41,149	-2,256 Reduced 5.71%	37,230 $482,000
Q2 2021 Aug 11, 2021	SELL	$15.83 - $17.84 $212,850 - $239,876	-13,446 Reduced 25.4%	39,486 $654,000
Q1 2021 May 07, 2021	BUY	$15.92 - $20.3 $8,501 - $10,840	534 Added 1.02%	52,932 $909,000
Q4 2020 Feb 03, 2021	BUY	$15.65 - $19.92 $241,557 - $307,465	15,435 Added 41.76%	52,398 $820,000
Q3 2020 Nov 04, 2020	SELL	$13.97 - $21.16 $33,472 - $50,699	-2,396 Reduced 6.09%	36,963 $706,000
Q2 2020 Aug 05, 2020	SELL	$10.39 - $16.07 $102,746 - $158,916	-9,889 Reduced 20.08%	39,359 $540,000
Q1 2020 May 06, 2020	SELL	$8.89 - $24.94 $303,682 - $851,950	-34,160 Reduced 40.96%	49,248 $523,000
Q4 2019 Feb 07, 2020	BUY	$8.33 - $19.95 $694,788 - $1.66 Million	83,408 New	83,408 $1.56 Million

4.87M

Ticker XBIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,439,300
Market Cap $114M
Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.